Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance.
The oral antitussive dextromethorphan is a clinically available N-methyl-D-aspartate receptor antagonist. Dextromethorphan has analgesic efficacy in the experimental formalin test, blocks the nociceptive activation of the immediate-early gene, c-fos proto-oncogene, and prevents and reverses the development of opiate analgesic tolerance in experimental models. These data suggest that dextromethorphan should be evaluated in a controlled clinical trial for analgesic efficacy in zoster-associated neuralgia.
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
K J
KJ
Elliott
M
M
Brodsky
A
A
Hyanansky
K M
KM
Foley
C E
CE
Inturrisi
D003915:Dextromethorphan / Q000627:therapeutic use*; D004361:Drug Tolerance; D006801:Humans; D009294:Narcotics / Q000009:adverse effects*; D009619:Nociceptors / Q000187:drug effects*; D010146:Pain / Q000188:drug therapy*; D000090063:Proto-Oncogene Mas
C000715470:MAS1 protein, human; D009294:Narcotics; D000090063:Proto-Oncogene Mas; D003915:Dextromethorphan